Endocrine ophthalmopathy and radioiodine therapy

References

• Chapman EM. History of the discovery and early use of radioactive iodine. JAMA 1983; 250: 2042–4
   PubMedGoogle Scholar
• Sawin CT, Becker DV. Radioiodine and the treatment of hyperthyroidism: The early history. Thyroid 1997; 7: 163–76
   PubMed Web of Science ®Google Scholar
• Pequegnat EP, Mayberry WE, McConahey WM, Wyse EP. Large doses of radioiodide in Graves’ disease: Effect on ophthalmopathy and long-acting thyroid stimulator. Mayo Clin Proc 1967; 42: 802–11
   PubMedGoogle Scholar
• Vestergaard H, Laurberg P. Radioiodine and aggravation of Graves’ ophthalmopathy. Lancet 1989; 2: 47
   PubMedGoogle Scholar
• Karlsson FA, Westermark K, Dahlberg PA, Jansson R, Enoksson P. Ophthalmopathy and thyroid stimulation. Lancet 1989; 2: 691
   PubMedGoogle Scholar
• Bartalena L, Marcocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A. Use of corticosteroids to prevent progression of Graves’ ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 1989; 321: 1349–52
   PubMed Web of Science ®Google Scholar
• Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H, et al. Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism. The Thyroid Study Group. N Engl J Med 1992; 326: 1733–8
   PubMed Web of Science ®Google Scholar
• Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell'Unto E, et al. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med 1998; 338: 73–8
   PubMed Web of Science ®Google Scholar
• Hagg E, Asplund K. Is endocrine ophthalmopathy related to smoking?. Br Med J 1987; 295: 634–5
   PubMed Web of Science ®Google Scholar
• Vestergaard P. Smoking and thyroid disorders- a meta-analysis. Eur J Endocrinol 2002; 146: 153–61
   PubMed Web of Science ®Google Scholar
• Winsa B, Adami HO, Bergstrom R, Gamstedt A, Dahlberg PA, Adamson U, et al. Stressful life events and Graves’ disease. Lancet 1991; 338: 1475–9
   PubMed Web of Science ®Google Scholar
• Smith BR, Hall R. Binding of thyroid stimulators to thyroid membranes. FEBS Lett 1974; 42: 301–4
   PubMedGoogle Scholar
• Parmentier M, Libert F, Maenhaut C, Lefort A, Gerard C, Perret J, et al. Molecular cloning of the thyrotropin receptor. Science 1989; 246: 1620–2
   PubMed Web of Science ®Google Scholar
• Nagayama Y, Kaufman KD, Seto P, Rapoport B. Molecular cloning, sequence and functional expression of the cDNA for the human thyrotropin receptor. Biochem Biophys Res Commun 1989; 165: 1184–90
   PubMed Web of Science ®Google Scholar
• Feliciello A, Porcellini A, Ciullo I, Bonavolonta G, Avvedimento EV, Fenzi G. Expression of thyrotropin-receptor mRNA in healthy and Graves’ disease retro-orbital tissue. Lancet 1993; 342: 337–8
   PubMed Web of Science ®Google Scholar
• Bahn RS, Dutton CM, Natt N, Joba W, Spitzweg C, Heufelder AE. Thyrotropin receptor expression in Graves’ orbital adipose/connective tissues: Potential autoantigen in Graves’ ophthalmopathy. J Clin Endocrinol Metab 1998; 83: 998–1002
   PubMed Web of Science ®Google Scholar
• Starkey KJ, Janezic A, Jones G, Jordan N, Baker G, Ludgate M. Adipose thyrotrophin receptor expression is elevated in Graves’ and thyroid eye diseases ex vivo and indicates adipogenesis in progress in vivo. J Mol Endocrinol 2003; 30: 369–80
   PubMed Web of Science ®Google Scholar
• Kopp P, van Sande J, Parma J, Duprez L, Gerber H, Joss E, et al. Brief report: Congenital hyperthyroidism caused by a mutation in the thyrotropin-receptor gene. N Engl J Med 1995; 332: 150–4
   PubMedGoogle Scholar
• de Roux N, Polak M, Couet J, Leger J, Czernichow P, Milgrom E, et al. A neomutation of the thyroid-stimulating hormone receptor in a severe neonatal hyperthyroidism. J Clin Endocrinol Metab 1996; 81: 2023–6
   PubMed Web of Science ®Google Scholar
• Ono S, Schwartz ID, Mueller OT, Root AW, Usala SJ, Bercu BB. Homozygosity for a dominant negative thyroid hormone receptor gene responsible for generalized resistance to thyroid hormone. J Clin Endocrinol Metab 1991; 73: 990–4
   PubMed Web of Science ®Google Scholar
• Wyse EP, McConahey WM, Woolner LB, Scholz DA, Kearns TP. Ophthalmopathy without hyperthyroidism in patients with histologic Hashimoto's thyroiditis. J Clin Endocrinol Metab 1968; 28: 1623–9
   PubMedGoogle Scholar
• Sung LC, McDougall IR. Graves’ hyperthyroidism. Spontaneous occurrence after autoimmune hypothyroidism with persistent infiltrative ophthalmopathy. Arch Intern Med 1978; 138: 1009–10
   PubMedGoogle Scholar
• Bech K, Bliddal H, Siersbaek-Nielsen K, Friis T. Production of non-stimulatory immunoglobulins that inhibit TSH binding in Graves’ disease after radioiodine administration. Clin Endocrinol (Oxf) 1982; 17: 395–402
   PubMedGoogle Scholar
• Yoshida K, Aizawa Y, Kaise N, Fukazawa H, Kiso Y, Sayama N, et al. Role of thyroid-stimulating blocking antibody in patients who developed hypothyroidism within one year after 131I treatment for Graves’ disease. Clin Endocrinol (Oxf) 1998; 48: 17–22
   PubMedGoogle Scholar
• Gamstedt A, Wadman B, Karlsson A. Methimazole, but not betamethasone, prevents 131I treatment-induced rises in thyrotropin receptor autoantibodies in hyperthyroid Graves’ disease. J Clin Endocrinol Metab 1986; 62: 773–7
   PubMedGoogle Scholar
• Ilicki A, Gamstedt A, Karlsson FA. Hyperthyroid Graves’ disease without detectable thyrotropin receptor antibodies. J Clin Endocrinol Metab 1992; 74: 1090–4
   PubMedGoogle Scholar
• Einhorn J, Fagraeus A, Jonsson J. Thyroid antibodies after 131-I treatment for hyperthyroidism. J Clin Endocrinol Metab 1965; 25: 1218–24
   PubMed Web of Science ®Google Scholar
• Karlsson FA, Dahlberg PA, Jansson R, Westermark K, Enoksson P. Importance of TSH receptor activation in the development of severe endocrine ophthalmopathy. Acta Endocrinol (Copenh) 1989; 121(Suppl 2)132–41
   Google Scholar
• Tallstedt L, Lundell G, Blomgren H, Bring J. Does early administration of thyroxine reduce the development of Graves’ ophthalmopathy after radioiodine treatment?. Eur J Endocrinol 1994; 130: 494–7
   PubMed Web of Science ®Google Scholar
• Eckstein AK, Plicht M, Lax H, Hirche H, Quadbeck B, Mann K, et al. Clinical results of anti-inflammatory therapy in Graves’ ophthalmopathy and association with thyroidal autoantibodies. Clin Endocrinol (Oxf) 2004; 61: 612–8
   PubMed Web of Science ®Google Scholar
• Winsa B, Rastad J, Akerstrom G, Johansson H, Westermark K, Karlsson FA. Retrospective evaluation of subtotal and total thyroidectomy in Graves’ disease with and without endocrine ophthalmopathy. Eur J Endocrinol 1995; 132: 406–12
   PubMedGoogle Scholar
• Jarhult J, Rudberg C, Larsson E, Selvander H, Sjovall K, Winsa B, et al. Graves’ disease with moderate-severe endocrine ophthalmopathy-long term results of a prospective, randomized study of total or subtotal thyroid resection. Thyroid. 2005; 15: 1157–64
   PubMedGoogle Scholar